يعرض 1 - 10 نتائج من 38 نتيجة بحث عن '"Fengjuan Xuan"', وقت الاستعلام: 2.10s تنقيح النتائج
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5

    المساهمون: Pulmonology, AII - Inflammatory diseases, Clinical sciences, Physiotherapy, Human Physiology and Anatomy, Pediatrics

    المصدر: Lancet, 394(10212), 1940-1948. Elsevier Limited
    VX17-445-103 Trial Group 2019, ' Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial ', Lancet, vol. 394, no. 10212, pp. 1940 . https://doi.org/10.1016/S0140-6736(19)32597-8
    Lancet
    The Lancet, 394(10212), 1940. Elsevier Limited

    مصطلحات موضوعية: Male, Indoles, Pyrrolidines, Cystic Fibrosis, Pyridines, Clinical Trial, Phase III, Phases of clinical research, Cystic Fibrosis Transmembrane Conductance Regulator, 030204 cardiovascular system & hematology, Quinolones, Aminophenols, Cystic fibrosis, law.invention, Ivacaftor, chemistry.chemical_compound, 0302 clinical medicine, Randomized controlled trial, law, 030212 general & internal medicine, Pyridines/administration & dosage, Non-U.S. Gov't, Chloride Channel Agonists, Sweat, Child, Chloride Channel Agonists/administration & dosage, Medicine(all), biology, Research Support, Non-U.S. Gov't, Lumacaftor, General Medicine, Indoles/administration & dosage, Clinical Trial, Cystic fibrosis transmembrane conductance regulator, Pyrrolidines/administration & dosage, Quinolones/administration & dosage, Randomized Controlled Trial, Combination, Drug Therapy, Combination, Female, medicine.drug, medicine.medical_specialty, Adolescent, Research Support, Article, Benzodioxoles/administration & dosage, Sweat/chemistry, N.I.H, 03 medical and health sciences, Phase III, Research Support, N.I.H., Extramural, Double-Blind Method, Drug Therapy, Internal medicine, Journal Article, medicine, Aminophenols/administration & dosage, Humans, Benzodioxoles, business.industry, Extramural, medicine.disease, Pyrazoles/administration & dosage, Clinical trial, Regimen, chemistry, biology.protein, Pyrazoles, Cystic Fibrosis Transmembrane Conductance Regulator/genetics, sense organs, Cystic Fibrosis/drug therapy, business

    وصف الملف: application/pdf; text/plain

  6. 6
  7. 7
  8. 8
  9. 9
  10. 10

    المصدر: Hortobagyi, G N, Stemmer, S M, Burris, H A, Yap, Y-S, Sonke, G S, Paluch-Shimon, S, Campone, M, Blackwell, K L, André, F, Winer, E P, Janni, W, Verma, S, Conte, P, Arteaga, C L, Cameron, D A, Petrakova, K, Hart, L L, Villanueva, C, Chan, A, Jakobsen, E, Nusch, A, Burdaeva, O, Grischke, E-M, Alba, E, Wist, E, Marschner, N, Favret, A M, Yardley, D, Bachelot, T, Tseng, L-M, Blau, S, Xuan, F, Souami, F, Miller, M, Germa, C, Hirawat, S & O’Shaughnessy, J 2016, ' Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer ', New England Journal of Medicine, vol. 375, no. 18, pp. 1738-1748 . https://doi.org/10.1056/NEJMoa1609709

    وصف الملف: application/pdf